Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study (CROSBI ID 309354)
Prilog u časopisu | kratko priopćenje | međunarodna recenzija
Podaci o odgovornosti
Pelchen-Matthews, A ; Larsen, J ; Shepherd, L ; Begovac, Josip ; Pedersen, K ; De Wit, S ; Horban, A ; Jablonowska, E ; Johnson, M ; Khromova, I ; Losso, M ; Nielsen, L ; Ridolfo, A ; Schmied, B ; Stephan, C ; Yust, I ; Vannappagari, V ; Ragone, L ; Roen, A ; Raben, D ; Kirk, O ; Peters, L ; Mocroft, A
EuroSIDA Study Group
engleski
Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study
Background: Hypersensitivity reaction (HSR) and hepatotoxicity are rare, but potentially serious side-effects of antiretroviral use.Objective: To investigate discontinuations due to HSR, hepatotoxicity or other reasons among users of dolutegravir (DTG) vs. raltegravir (RAL) or elvitegravir (EVG) in the EuroSIDA cohort.Methods: We compared individuals ≥18 years and starting combination antiretroviral therapy (ART, ≥3 drugs) with DTG vs. RAL or EVG, with or without abacavir (ABC), between January 16, 2014 and January 23, 2019. Discontinuations due to serious adverse events (SAEs) were independently reviewed.Results: Altogether 4366 individuals started 5116 ART regimens including DTG, RAL, or EVG, contributing 9180 person-years of follow-up (PYFU), with median follow-up 1.6 (interquartile range 0.7-2.8) years per treatment episode. Of these, 3074 (60.1%) used DTG (1738 with ABC, 1336 without) and 2042 (39.9%) RAL or EVG (286 with ABC, 1756 without). 1261 (24.6%) INSTI episodes were discontinued, 649 of the DTG-containing regimens (discontinuation rate 115, 95% CI 106-124/1000 PYFU) and 612 RAL or EVG- containing regimens (173, CI 160-188/1000 PYFU). After independent review, there were five HSR discontinuations, two for DTG (one with and one without ABC, discontinuation rate 0.35, CI 0.04- 1.28/1000 PYFU), and three for RAL or EVG without ABC (0.85, CI 0.18-2.48/1000 PYFU). There was one hepatotoxicity discontinuation on DTG with ABC (discontinuation rate 0.18, CI 0.00-0.99/1000 PYFU).Conclusion: During 5 years of observations in the EuroSIDA cohort independently reviewed discontinuations due to HSR or hepatotoxicity were very rare, indicating a low rate of SAEs.
human immunodeficiency virus ; antiretroviral therapy ; dolutegravir ; hepatotoxicity ; hypersensitivity reaction ; integrase strand transfer inhibitors ; serious adverse events
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
22 (6)
2021.
160-168
objavljeno
2578-7470
10.1080/25787489.2021.2003132
Povezanost rada
Kliničke medicinske znanosti